Northern Star’s Elliott-fueled run comes up against post-holiday session

Northern Star’s Elliott-fueled run comes up against post-holiday session

June 8, 2026

Sydney, June 9, 2026, 04:05 AEST

Northern Star Resources heads into Tuesday trading still coming off its Elliott-driven run. The shares finished at A$19.88 on Friday, falling 2.5%. ASX stays shut Monday for the King’s Birthday—June 8 is listed as a holiday on the exchange’s 2026 calendar.

Ahead of the next trade, investors are watching to see if Northern Star is still in play as a sale target, or if the story now is just a gold miner with production misses, cost issues, and an unfinished CEO search. Shares ended last week under A$20.

Elliott Investment Management has taken a stake of more than 4% in Northern Star worth over A$1 billion and called for a strategic review that could mean anything from asset sales to a company sale or a turnaround on its own. Shares were up 13.7% after the news. “The company does need to be shaken up,” Brenton Saunders, a portfolio manager at Pendal Group, told Reuters, saying Elliott’s approach is “very effective, if somewhat unorthodox.” Reuters

Northern Star is pushing to calm nerves. The miner said in a June 2 ASX statement that it welcomes talks with Elliott and has hired an international search firm to look for a new managing director. Northern Star still expects to commission the KCGM Mill Expansion at the start of FY27. Goldman Sachs is advising the board on deals, portfolio changes, and bigger M&A options, the company said.

S&P/ASX 200 gave up 0.70% to close at 8,625.10 on Friday. Miners and banks pulled the index lower ahead of Monday’s holiday. Broader market moves were muted.

Pressure from rivals is at the center of Elliott’s push. Morningstar analyst Jon Mills said on June 4, “We think Northern Star is now in play,” but he still held his A$15 fair value target and agreed Elliott had “a valid point” about Northern Star lagging Newmont, Evolution and Perseus. Mills pointed to Kalgoorlie production problems, more spending, and multiple guidance cuts. Morningstar

But the trade can move the other direction. Reuters reported spot gold was at $4,330.98 an ounce on Monday after bouncing from earlier lows. U.S. August gold futures edged down 0.2%. If U.S. inflation comes in hot this week, rate-hike bets could rise and pressure non-yielding gold. Any delay with the CEO search or KCGM schedule would shift attention back to output, costs, and how well things get done.

Looking at the week ahead, the first thing for investors is to see how much of Tuesday’s open bakes in a takeover premium. After that, the question is whether Elliott shifts the valuation case, or if this was just a quick rally in a stock that will still trade on guidance, shipment flow and where gold heads next.

Stock Market Today

  • New Drug Apitegromab May Prevent Muscle Loss from Obesity GLP-1 Treatments
    June 8, 2026, 2:04 PM EDT. A new drug, apitegromab, shows promise in reducing muscle loss associated with GLP-1 obesity medications like Ozempic, Wegovy, and Mounjaro, which can cause unwanted muscle decline known as 'Ozempic butt.' In a six-month U.S. trial involving 102 adults, participants receiving apitegromab alongside Mounjaro retained 55% more muscle mass while still achieving fat loss. Muscle preservation is crucial since unlike fat, muscle is harder to regain. Apitegromab, administered via infusion, blocks a protein that triggers muscle breakdown and is under investigation for other muscle-related conditions. Experts urge caution, calling for larger and longer studies to confirm benefits such as improved strength and health outcomes. The treatments remain appetite suppressants and are not intended for short-term cosmetic use.